2. Search Result
Search Result
Results for "

tak-

" in MedChemExpress (MCE) Product Catalog:

203

Inhibitors & Agonists

2

Biochemical Assay Reagents

10

Peptides

11

Inhibitory Antibodies

15

Natural
Products

4

Protéines recombinantes

8

Isotope-Labeled Compounds

16

Antibodies

1

Oligonucleotides

Cat. No. Nom du produit Target Áreas de investigación Chemical Structure
  • HY-111789
    Subasumstat
    30+ Cited Publications

    tak-981

    		 E1/E2/E3 Enzyme Inflammation/Immunology Cancer
    Subasumstat (TAK-981) is a first in class and selective inhibitor of the SUMOylation enzymatic cascade, with potential immune-activating and antineoplastic activities .
    Subasumstat
  • HY-100487
    TAK-243
    80+ Cited Publications

    MLN7243

    		 E1/E2/E3 Enzyme NF-κB Apoptosis Cancer
    TAK-243 (MLN7243) is a first-in-class, selective ubiquitin activating enzyme, UAE (UBA1) inhibitor (IC50=1 nM), which blocks ubiquitin conjugation, disrupting monoubiquitin signaling as well as global protein ubiquitination. TAK-243 (MLN7243) induces endoplasmic reticulum (ER) stress, abrogates NF-κB pathway activation and promotes apoptosis .
    TAK-243
  • HY-13328
    Sapanisertib
    50+ Cited Publications

    INK-128; MLN0128; tak-228

    		 mTOR Autophagy Cancer
    Sapanisertib (INK-128; MLN0128; TAK-228) is an orally available, ATP-dependent mTOR1/2 inhibitor with an IC50 of 1 nM for mTOR kinase.
    Sapanisertib
  • HY-15246
    Tovorafenib
    5+ Cited Publications

    tak-580; MLN 2480; BIIB-024

    		 Raf Cancer
    Tovorafenib (TAK-580, MLN 2480) is an orally active and selective inhibitor of pan-Raf kinase. Tovorafenib can be used for the study of glioma .
    Tovorafenib
  • HY-10480
    Fasiglifam
    15+ Cited Publications

    tak-875

    		 Free Fatty Acid Receptor Metabolic Disease
    Fasiglifam (TAK-875) is a potent, selective and orally bioavailable GPR40 agonist with EC50 of 72 nM.
    Fasiglifam
  • HY-14882
    Cenicriviroc
    5+ Cited Publications

    tak-652; TBR-652

    		 CCR HIV Infection Endocrinology
    Cenicriviroc (TAK-652) is an orally active, dual CCR2/CCR5 antagonist, also inhibits both HIV-1 and HIV-2, and displays potent anti-inflammatory and antiinfective activity .
    Cenicriviroc
  • HY-15295
    Vonoprazan Fumarate
    5+ Cited Publications

    tak-438

    		 Proton Pump Metabolic Disease Cancer
    Vonoprazan Fumarate (TAK-438), a proton pump inhibitor (PPI), is a potent and orally active potassium-competitive acid blocker (P-CAB), with antisecretory activity. Vonoprazan Fumarate inhibits H +,K +-ATPase activity in porcine gastric microsomes with an IC50 of 19 nM at pH 6.5. Vonoprazan Fumarate is developed for the research of acid-related diseases, such as gastroesophageal reflux disease and peptic ulcer disease .
    Vonoprazan Fumarate
  • HY-15160
    TAK-960
    2 Publications Verification

    		 Polo-like Kinase (PLK) Cancer
    TAK-960 is an orally available, selective inhibitor of polo-like kinase 1 (PLK1), with an IC50 of 0.8 nM. TAK-960 also shows inhibitory activities against PLK2 and PLK3, with IC50s of 16.9 and 50.2 nM, respectively. TAK-960 inhibits proliferation of multiple cancer cell lines and exhibits significant efficacy against multiple tumor xenografts .
    TAK-960
  • HY-16474
    Relugolix

    tak-385

    		 GnRH Receptor Endocrinology Cancer
    Relugolix (TAK-385)?is a potent, orally active, nonpeptidic gonadotropin-releasing hormone (GnRH) antagonist. Relugolix possesses high affinity and potent antagonistic activity for human receptor (binding IC50=0.33 nM) and monkey receptor (IC50=0.32 nM) compared with TAK-013 (HY-100209) . Relugolix is used for the study of sex-hormone-dependent diseases, such as including endometriosis, uterine fibroids and prostate cancer et al .
    Relugolix
  • HY-159835
    Oveporexton

    tak-861

    		 Orexin Receptor (OX Receptor) Neurological Disease
    Oveporexton (TAK-861) is an orally active and selective orexin receptor 2 (OX2R) agonist with an EC50 of 2.5 nM. Oveporexton exhibits 3000-fold selectivity for OX2R over OX1R. Oveporexton can be used for the study of hypersomnia disorders including narcolepsy .
    Oveporexton
  • HY-14737
    Ceftaroline fosamil
    2 Publications Verification

    tak-599; PPI0903

    		 Bacterial Antibiotic Infection
    Ceftaroline fosamil (TAK-599), a cephalosporin derivative, is an N-phosphono proagent of anti-methicillin-resistant Staphylococcus aureus (MRSA) T-91825. Ceftaroline fosamil can be used for the research of MRSA infection .
    Ceftaroline fosamil
  • HY-135815
    Mobocertinib
    10+ Cited Publications

    tak-788; AP32788

    		 EGFR Cancer
    Mobocertinib (TAK-788) is an orally active and irreversible EGFR/HER2 inhibitor. Mobocertinib potently inhibits oncogenic variants containing activating EGFRex20ins mutations with selectivity over wild-type EGFR. Mobocertinib can be used in NSCLC research .
    Mobocertinib
  • HY-13406
    TAK-779
    10+ Cited Publications

    takeda 779

    		 CCR HIV CXCR Infection Inflammation/Immunology Endocrinology
    TAK-779 is a potent and selective nonpeptide antagonist of CCR5 and CXCR3, with a Ki of 1.1 nM for CCR5, and effectively and selectively inhibits R5 HIV-1, with EC50 and EC90 of 1.2 nM and 5.7 nM, respectively, in MAGI-CCR5 cells.
    TAK-779
  • HY-10456
    TAK-715
    10+ Cited Publications

    		 p38 MAPK Casein Kinase Wnt Inflammation/Immunology
    TAK-715 is an orally active and potent p38 MAPK inhibitor with IC50s of 7.1 nM, 200 nM for p38α and p38β, respectively. TAK-715 inhibits casein kinase I (CK1δ/ε) to regulate activation of Wnt/β-catenin signaling. TAK-715 shows good significant efficacy in a rat arthritis model .
    TAK-715
  • HY-13449
    TAK-733
    5+ Cited Publications

    		 MEK Cancer
    TAK-733 is a potent and selective MEK allosteric site inhibitor with an IC50 of 3.2 nM.
    TAK-733
  • HY-13501
    Mubritinib
    5+ Cited Publications

    tak-165

    		 EGFR Cancer
    Mubritinib (TAK-165) is a potent and selective EGFR2/HER2 inhibitor with an IC50 of 6 nM.
    Mubritinib
  • HY-100888
    Simurosertib
    10+ Cited Publications

    tak-931

    		 CDK Cancer
    Simurosertib (TAK-931) is an orally active, selective and ATP-competitive cell division cycle 7 (CDC7) kinase inhibitor, with an IC50 of <0.3 nM. Simurosertib has anti-cancer activity .
    Simurosertib
  • HY-133898
    Danavorexton

    tak-925

    		 Orexin Receptor (OX Receptor) Others
    Danavorexton (TAK-925) is an orexin receptor agonist with brain permeability. Danavorexton induces a physiological pattern of OX2R activation in vitro to wake up sleepy mice and improve sleepiness symptoms .
    Danavorexton
  • HY-16274
    Lapaquistat acetate
    1 Publications Verification

    tak-475

    		 Farnesyl Transferase Metabolic Disease
    Lapaquistat acetate (TAK-475) is a squalene synthase inhibitor, blocking the conversion of farnesyl diphosphate (FPP) to squalene in the cholesterol biosynthesis pathway . Lapaquistat acetate is effective at lowering low-density lipoprotein cholesterol, but it might cause liver damage. Lapaquistat acetate is used for hypercholesterolemia and mevalonate kinase deficiency (MKD) research .
    Lapaquistat acetate
  • HY-115864
    Osavampator

    tak-653; NBI-1065845

    		 iGluR Lipoxygenase Neurological Disease
    Osavampator (TAK-653) is a AMPA receptor positive allosteric modulator. Osavampator selectively binds to AMPA-R in a glutamate-dependent manner and induces Ca2+ influx in hGluA1i CHO cells (EC50 = 3.3 μM). Osavampator improves learning and memory in many models. Osavampator is can be used for the research of depressive disorders .
    Osavampator
  • HY-15196
    TAK-285
    3 Publications Verification

    		 EGFR Cancer
    TAK-285 is a potent, selective, ATP-competitive and orally active HER2 and EGFR(HER1) inhibitor with IC50 of 17 nM and 23 nM, respectively. TAK-285 is >10-fold selectivity for HER1/2 than HER4, and less potent to MEK1/5, c-Met, Aurora B, Lck, CSK etc. TAK-285 has effective antitumor activity . TAK-285 can cross the blood-brain barrier (BBB) .
    TAK-285
  • HY-12472
    Balipodect
    2 Publications Verification

    tak-063

    		 Phosphodiesterase (PDE) Infection Neurological Disease Cancer
    Balipodect (TAK-063) is a selective, brain-penetrant and orally active PDE10A inhibitor with an IC50 of 0.30 nM. Balipodect shows >15000-fold selectivity over other PDEs. Balipodect elevates striatal cAMP and cGMP levels in mice. Balipodect can be used for the study of schizophrenia[1].
    Balipodect
  • HY-109123
    Soticlestat

    tak-935; OV935

    		 Cytochrome P450 Neurological Disease
    Soticlestat (TAK-935; OV935) is a first-in-class, potent, selective, and orally active cholesterol 24-hydroxylase (CH24H) inhibitor. Soticlestat has the potential for epilepsy syndromes research .
    Soticlestat
  • HY-148029
    Dazostinag disodium

    tak-676

    		 STING Cancer
    Dazostinag disodium (TAK-676) is an agonist of STING, triggering the activation of STING signaling pathway and type I interferons. Dazostinag disodium is also a modulator of immune system, resulting complete regressions and durable memory T-cell immunity. Dazostinag disodium promotes durable IFN-dependent antitumor immunity .
    Dazostinag disodium
  • HY-14882A
    Cenicriviroc Mesylate
    5+ Cited Publications

    tak-652 Mesylate; TBR-652 Mesylate

    		 CCR HIV Infection Inflammation/Immunology Endocrinology
    Cenicriviroc Mesylate (TAK-652 Mesylate) is a dual CCR2/CCR5 antagonist, also inhibits both HIV-1 and HIV-2, and displays potent anti-inflammatory and antiinfective activity.
    Cenicriviroc Mesylate
  • HY-14914
    Azilsartan
    5+ Cited Publications

    tak-536

    		 Angiotensin Receptor Reactive Oxygen Species (ROS) Apoptosis Cardiovascular Disease Neurological Disease Metabolic Disease Cancer
    Azilsartan (TAK-536) is an orally active, potent, selective and specific angiotensin II type 1 receptor (AT1) antagonist. Azilsartan induces ROS formation and apoptosis in HepG2 cells. Azilsartan shows neuroprotective and anticancer activity. Azilsartan can be used for hypertension and stroke research .
    Azilsartan
  • HY-122190
    TAK-071

    		mAChR Neurological Disease
    TAK-071 is a novel, potent and highly selective muscarinic acetylcholine receptor 1 (M1R) positive allosteric modulator. EC50 of TAK-071 M1R agonist activities is 520 nM .
    TAK-071
  • HY-12201
    TAK-901
    5 Publications Verification

    		 Aurora Kinase Cancer
    TAK-901 is a multi-targeted aurora inhibitor with IC50s of 21 and 15 nM for aurora A and B, respectively.
    TAK-901
  • HY-15767
    TAK-632
    4 Publications Verification

    		 Raf Aurora Kinase Cancer
    TAK-632 is a potent pan-RAF inhibitor with IC50 of 1.4, 2.4 and 8.3 nM for CRAF, BRAF V600E, BRAF WT, respectively.
    TAK-632
  • HY-15506
    TAK-593
    1 Publications Verification

    		 PDGFR VEGFR Cancer
    TAK-593 is a potent VEGFR and PDGFR family inhibitor with IC50s of 3.2, 0.95, 1.1, 4.3 and 13 nM for VEGFR1, VEGFR2, VEGFR3, PDFGRα and PDFGRβ, respectively.
    TAK-593
  • HY-100867A
    Mivavotinib monohydrochloride

    tak-659 monohydrochloride; CB-659 monohydrochloride

    		 Syk FLT3 Cancer
    TAK-659 hydrochloride is a highly potent, selective, reversible and orally available dual inhibitor of spleen tyrosine kinase (SYK) and fms related tyrosine kinase 3 (FLT3), with an IC50 of 3.2 nM and 4.6 nM for SYK and FLT3, respectively. TAK-659 hydrochloride induces cell death in tumor cells but not in nontumor cells, and with potential for the treatment of chronic lymphocytic leukemia (CLL) .
    Mivavotinib monohydrochloride
  • HY-P991442
    DNL-919

    tak-920

    		 TREM receptor Neurological Disease
    DNL-919 (TAK-920) is a human IgG1 monoclonal antibody (mAb) targeting TREM-2. DNL-919 can be used in Alzheimer's disease research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
    DNL-919
  • HY-P2161B
    TAK-683 acetate
    4 Publications Verification

    		 Kisspeptin Receptor Cancer
    TAK-683 acetate is a potent full KISS1 receptor (KISS1R) agonist (IC50=170 pM) with improved metabolic stability. TAK-683 acetate is a nonapeptide metastin analog, exhibits agonistic activities to KISS1R with EC50 values of 0.96 nM and 1.6 nM for human and rat, respectively . TAK-683 acetate depletes GnRH in the hypothalamus and reduces plasma FSH, LH, and testosterone levels in vivo, it has the potential for the study of hormone-dependent prostate cancer .
    TAK-683 acetate
  • HY-100209
    Sufugolix

    tak-013

    		 GnRH Receptor Endocrinology
    Sufugolix (TAK-013) is a highly potent and orally available luteinizing hormone-releasing hormone (LHRH) receptor antagonist with an IC50 of 0.1 nM.
    Sufugolix
  • HY-132228
    Zelatriazin

    tak-041; NBI-1065846

    		 GPR139 Neurological Disease
    Zelatriazin (TAK-041; NBI-1065846) is a potent and selective GPR139 agonist with an EC50 of 22 nM. Zelatriazin has the potential for the research of negative symptoms associated with schizophrenia .
    Zelatriazin
  • HY-138830
    TAK-418
    2 Publications Verification

    		 Histone Demethylase Neurological Disease
    TAK-418 is a selective, orally active LSD1 (KDM1A) enzyme inhibitor with an IC50 of 2.9 nM. TAK-418 unlocks aberrant epigenetic machinery and improves autism symptoms in neurodevelopmental disorder models .
    TAK-418
  • HY-122642
    TAK1-IN-4

    		MAP3K Inflammation/Immunology
    TAK1-IN-4 (Compound 14) is a TAK1 inhibitor .
    TAK1-IN-4
  • HY-P0076
    TAK-448
    3 Publications Verification

    MVT-602

    		 Kisspeptin Receptor Cancer
    TAK-448 (MVT-602) is a potent and full KISS1R agonist with an IC50 of 460 pM and an EC50 of 632 pM .
    TAK-448
  • HY-P0076A
    TAK-448 acetate
    3 Publications Verification

    MVT-602 acetate

    		 Kisspeptin Receptor Cancer
    TAK-448 acetate (MVT-602 acetate) is a potent and full KISS1R agonist with an IC50 of 460 pM and an EC50 of 632 pM .
    TAK-448 acetate
  • HY-137440A
    Firazorexton hydrate

    tak-994

    		 Orexin Receptor (OX Receptor) ERK Neurological Disease
    Firazorexton hydrate (TAK-994) is an orally active and brain-penetrant orexin type 2 receptor (OX2R) selective agonist. Firazorexton hydrate can promote wakefulness and has the potential to improve narcolepsy-like symptoms in mice .
    Firazorexton hydrate
  • HY-P99730
    Mezagitamab
    1 Publications Verification

    tak-079

    		 CD38 Apoptosis Inflammation/Immunology Cancer
    Mezagitamab (TAK-079) is a IgG1λ anti-CD38 monoclonal antibody. Mezagitamab depletes tumor cells expressing CD38 through antibody and complement dependent cytotoxicity. Mezagitamab has potential application in relapsed/refractory multiple myeloma (RRMM) and idiopathic thrombocytopenic purpura (ITP) .
    Mezagitamab
  • HY-109183
    Luvadaxistat

    tak-831

    		 Xanthine Oxidase Others
    Luvadaxistat (TAK-831) is an orally active, highly selective, potent D-amino acid oxidase (DAAO) inhibitor. Luvadaxistat inhibits oxidative deamination of D-serine via the human recombinant DAAO enzyme with an IC50 of 14 nM. Luvadaxistat significantly increases D-serine levels in the rodent brain, plasma, and cerebrospinal fluid. Luvadaxistat has the potential for schizophrenia research .
    Luvadaxistat
  • HY-19974
    TAK-220
    3 Publications Verification

    		 CCR HIV Infection Endocrinology
    TAK-220 is a selective and orally bioavailable CCR5 antagonist, with IC50s of 3.5 nM and 1.4 nM for inhibition on the binding of RANTES and MIP-1α to CCR5, respectively, but shows no effect on the binding to CCR1, CCR2b, CCR3, CCR4, or CCR7; TAK-220 also selectively inhibits HIV-1, with EC50s of 1.2 nM (HIV-1 KK), 0.72 nM (HIV-1 CTV), 1.7 nM (HIV-1 HKW), 1.7 nM (HIV-1 HNK), 0.93 nM (HIV-1 HTN), and 0.55 nM (HIV-1 HHA), and EC90s of 12 nM (HIV-1 KK), 5 nM (HIV-1 CTV), 12 nM (HIV-1 HKW), 28 nM (HIV-1 HNK), 15 nM (HIV-1 HTN), and 4 nM (HIV-1 HHA) in PBMCs.
    TAK-220
  • HY-77251
    TAK1/MAP4K2 inhibitor 1
    1 Publications Verification

    		 MAP4K MAP3K Cancer
    TAK1/MAP4K2 inhibitor 1 is a potent dual TGFβ-activated kinase 1 (TAK1) and mitogen-activated protein kinase kinase kinase kinase 2 (MAP4K2) inhibitor, with IC50s of 41.1 nM and 18.2 nM, respectively.
    TAK1/MAP4K2 inhibitor 1
  • HY-169949
    TAK-756

    		MAP3K NF-κB MMP Leukotriene Receptor Inflammation/Immunology
    TAK-756 is a selective transforming growth factor β-activated kinase 1 (TAK1) inhibitor with a target pIC50 of 8.6. TAK-756 can inhibit TAK1 autophosphorylation and downstream NF-κB phosphorylation, suppress the production of inflammatory and catabolic factors such as MMP-3 and IL-6. TAK-756 exhibits anti-inflammatory effects in a rat joint inflammation model. TAK-756 can be used for the research of inflammatory joint disease, osteoarthritis .
    TAK-756
  • HY-103493
    TAK-915

    		Phosphodiesterase (PDE) Neurological Disease
    TAK-915 is a potent, selective, brain-penetrant and orally active phosphodiesterase 2A (PDE2A) inhibitor with an IC50 of 0.61 nM. TAK-915 is >4100-fold more selectivity for PDE2A than PDE1A. TAK-915 has the potential for neuropsychiatric and neurodegenerative disorders treatment .
    TAK-915
  • HY-117959
    TAK-615

    		LPL Receptor Inflammation/Immunology
    TAK-615 is a negative allosteric modulator (NAM) of the LPA1 receptor for the research of pulmonary fibrosis. TAK-615 binds the LPA1 receptor with high affinity (Kd high affinity of 1.7 nM and Kd low affinity of 14.5 nM) .
    TAK-615
  • HY-132879
    TAK-020

    		Btk Inflammation/Immunology
    TAK-020 is a covalent Btk inhibitor, which becomes the clinical candidate.
    TAK-020
  • HY-115743
    TAK1-IN-3

    		MAP3K Cancer
    TAK1-IN-3 is a potent ATP-competitive TAK1 inhibitor.
    TAK1-IN-3
  • HY-132172
    TAK1-IN-2

    		MAP3K Cancer
    TAK1-IN-2 is a potent and selective TAK1 inhibitor, with an IC50> of 2 nM .
    TAK1-IN-2

Demande en ligne

Your information is safe with us. * Required Fields.

Civilité

  

Country or Region *

Nom du demandeur *

 

Nom de l'organisation *

Department *

     

Adresse e-mail *

 

Nom du produit *

Cat. No.

  

Requested quantity *

Numéro de téléphone *

     

Remarques

Demande en ligne

Inquiry Information

Nom du produit:
Cat. No.:
Quantité:
MCE Japan Authorized Agent: